Guillermo Urdaneta
Autonomous University of Barcelona
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Guillermo Urdaneta.
European Urology | 2010
Antonio Rosales; J. Salvador; Guillermo Urdaneta; Dyler Patiño; M. Montlleó; S. Esquena; Jorge Caffaratti; Javier Ponce de León; Luis Guirado; Humberto Villavicencio
We present the details of the first laparoscopic transplantation of a kidney from a living, related donor, performed April 16, 2009. Surgical and functional results were acceptable. Surgical time was 240 min (53 min for vascular suture), with blood loss of 300 cm(3) and a hospital stay of 14 d. Serum creatinine at discharge was 73 mmol/l. Laparoscopic kidney transplantation is a complex technique that requires previous experience in vascular and laparoscopic surgery. As with all novel procedures, technical modifications will be required to formalize its use and detailed comparisons will need to be made with standard procedures.
The Journal of Urology | 2011
Oscar Rodríguez Faba; J. Palou; Antonio Rosales; A. Breda; Ferran Algaba; Guillermo Urdaneta; H. Villavicencio
PURPOSE We evaluated new pre-cystectomy predictive factors for outcomes in patients with no evidence of residual tumor at cystectomy (pT0). MATERIALS AND METHODS A total of 1,114 patients underwent radical cystectomy at our institution between August 1978 and June 2002, of whom 141 (12.66%) had stage pT0. We analyzed overall and disease specific survival in relation to pre-cystectomy predictive factors, such as clinical stage, grade, size, previous nonmuscle invasive disease, number of previous recurrences, associated carcinoma in situ and lymphovascular invasion in the transurethral resection. Other factors analyzed were lymph node (N+) at cystectomy and induction chemotherapy. RESULTS Clinical stage was cTa in 10 patients, cT1 in 34, cT2 in 55, cT3 in 30 and cTis in 12. At a median followup of 42.5 months overall survival was 62.53% and disease specific survival was 79.14%. Metastatic disease developed in 17 cases (12.1%). Univariate analysis revealed worse disease specific survival in patients in whom muscle invasive tumor developed after nonmuscle invasive disease (p<0.05), and in those who presented with 5 or more previous recurrences (p<0.05), lymphovascular invasion in the transurethral resection (p<0.05) and N+ at cystectomy (p<0.05). Multivariate analysis confirmed a statistically significant association between disease specific survival and 5 or more previous recurrences (HR 1.5, 95% CI 1.07-2.10, p=0.018), muscle invasive tumor after nonmuscle invasive disease (HR 4.4, 95% CI 1.20-16.5, p=0.026) and lymphovascular invasion in the transurethral resection (HR 1.7, 95% CI 1.12-2.30, p=0.04). CONCLUSIONS Although clinical outcomes in patients with stage pT0 disease are often excellent, metastatic disease develops in a percentage of them. Muscle invasive tumor after primary nonmuscle invasive disease, 5 or more previous recurrences and lymphovascular invasion in the transurethral resection predict poor survival.
International Braz J Urol | 2011
Oscar Rodríguez Faba; Joan Palou; Guillermo Urdaneta; L. Gausa; H. Villavicencio
PURPOSE Describe morbidity and survival in patients older than 80 years with muscle invasive bladder cancer (MIBC) treated with radical cystectomy (RC) or transurethral resection (TUR) in our institution. MATERIALS AND METHODS We reviewed our database of all patients older than 80 years treated with RC and TUR for MIBC between 1993 and 2005 in our institution. Twenty-seven patients were submitted to RC, with mean age of 82 years and mean follow-up of 16.4 months. RC was carried out following diagnosis of previous MIBC in 14 cases (51.9%). The American Society of Anesthesiology (ASA) score was III or IV in 23 patients (85.1%). Seventy-two patients with a mean age of 84 years and mean follow-up of 33 months, diagnosed with MIBC, were managed by means of TUR. The ASA score was III-IV in 64 (88.8%) patients. RESULTS Pathological stage of the RC specimen was pT3 in 18 cases (66.7%). Mean hospital stay was 16 days. Early complications were assessed in 8 patients (29.6%), with an overall survival (OS) of 42.94%, and cancer-specific survival (CSS) of 60.54%. In patients submitted to TUR, clinical stage was T2 in 36 cases (50%). The mean hospital stay was 7 days, with a readmission rate (RR) of 87.5%. OS and CSS was less than 20%. CONCLUSIONS RC in octogenarian patients is a safe procedure, with complication and survival rates comparable to RC series in general population. Transurethral resection (TUR) for patients with MIBC within this age range is a much less morbid procedure, but disease specific survival is lower.
European Urology Supplements | 2008
Guillermo Urdaneta; Eduardo Solsona; J. Palou
European Urology Supplements | 2009
L. Sos; J. Palou; J. Huguet; Guillermo Urdaneta; A. Rosales; Ferran Algaba; A. Oliver; S. Esquena; H. Villavicencio
The Journal of Urology | 2007
O. Rodríguez; Juan Palau; Guillermo Urdaneta; Jorge Huguet; Antonio Rosales; Juan J. Gómez; Humberto Villavicencio
The Journal of Urology | 2011
J. Palou; Lluís Gausa; Guillermo Urdaneta; Miriam Serrano; Oscar Rodriguez Faba; Humberto Villavicencio
European Urology Supplements | 2011
A. Rosales; Guillermo Urdaneta; J. Salvador; S. Esquena; M. Montlleó; H. Villavicencio
European Urology Supplements | 2011
A. Rosales; J. Salvador; Guillermo Urdaneta; Mario Serrano; M. Montlleó; Jorge Caffaratti; J. Ponce De León; A. Breda; J.M. Díaz; H. Villavicencio
European Urology Supplements | 2011
J. Palou; L. Gausa; Guillermo Urdaneta